Bicalutamide is an orally active, non-steroidal androgen receptor (AR) antagonist used in prostate cancer research.
Synonyms: ICI 176334; ZD 176334; Abbreviation
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
50mg | łÇǶÊÊ | Inquiry | Inquiry | |
250mg | łÇò¶ÊÊ | Inquiry | Inquiry | |
1g | łËó¶ÊÊ | Inquiry | Inquiry | |
5g | łóď¶ÊÊ | Inquiry | Inquiry | |
25g | ł§ÊͶÊÊ | Inquiry | Inquiry | |
100g | łîÇʶÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
łÇǶÊÊ
łÇò¶ÊÊ
łËó¶ÊÊ
łóď¶ÊÊ
ł§ÊͶÊÊ
łîÇʶÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 90357-06-5 |
Formula : | C18H14F4N2O4S |
M.W : | 430.37 |
SMILES Code : | O=C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)C(C)(O)CS(=O)(C2=CC=C(F)C=C2)=O |
Synonyms : |
ICI 176334; ZD 176334; Abbreviation
|
MDL No. : | MFCD00869971 |
InChI Key : | LKJPYSCBVHEWIU-UHFFFAOYSA-N |
Pubchem ID : | 2375 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | Reference |
PC3 | 30 μM | 48 h | Bicalutamide inhibited the growth of PC3 cells, and a significant inhibition of cell growth was observed when combined with Curcumin. | PMC4446835 |
DU145 | 30 μM | 48 h | Bicalutamide inhibited the growth of DU145 cells, and a significant inhibition of cell growth was observed when combined with Curcumin. | PMC4446835 |
LNCaP | 30 μM | 48 h | Bicalutamide inhibited the growth of LNCaP cells, and a significant inhibition of cell growth was observed when combined with Curcumin. | PMC4446835 |
Rat mesangial cells (RMC) | 30 μM and 60 μM | 24 hours | Bicalutamide enhanced lactate dehydrogenase release, reactive oxygen species (ROS) production, lysosome population, and kidney injury molecule-1, and decreased N-cadherin. Bicalutamide elicited mitochondrial swelling and reduced the mitochondrial potential, resulting in severe suppression of the oxygen consumption rate (OCR), maximum respiration, and ATP production. | PMC7247665 |
LNCaP cells | 1.0 µM | 12 days | SPH potentiated the anti-proliferative effect of Bicalutamide on LNCaP cells, with relative colony survival decreasing from 25% to 2% in the presence of 160 µg/mL SPH and 1.0 µM Bicalutamide. | PMC9032914 |
PC3 cells | 10.0 µM | 12 days | SPH potentiated the anti-proliferative effect of Bicalutamide on PC3 cells, with relative colony survival decreasing from 52% to 32% in the presence of 160 µg/mL SPH and 10.0 µM Bicalutamide. | PMC9032914 |
LNCaP cells | 1 µM - 40 µM | 12 months | Generated bicalutamide resistant LNCaP cells (LNCaP-BicR) and found that these resistant cells express significantly increased levels of AR variants, particularly AR-V7, both at the mRNA and protein levels. | PMC5544572 |
CWR22Rv1 cells | 20 µM | 3 and 5 days | Niclosamide and bicalutamide combination treatment significantly suppressed the growth of CWR22Rv1 cells and induced apoptosis. | PMC5544572 |
C4-2B MDVR cells | 20 µM | 3 and 5 days | Niclosamide and bicalutamide combination treatment significantly suppressed the growth of C4-2B MDVR cells and induced apoptosis. | PMC5544572 |
LNCaP cells | 30 µM | 7 days | Investigated the effect of Bicalutamide on LNCaP cells, finding that Bicalutamide increased the expression of ERα and NRF2, and decreased the expression of AR. | PMC9661764 |
IPC-366 | 100 nM | 24 hours | To evaluate the effect of bicalutamide combined with docetaxel on cell proliferation and migration. Results showed that the combination of bicalutamide and docetaxel significantly reduced proliferation and migration in IPC-366 cells. | PMC11276844 |
SUM149 | 100 nM | 24 hours | To evaluate the effect of bicalutamide combined with docetaxel on cell proliferation and migration. Results showed that the combination of bicalutamide and docetaxel significantly reduced proliferation and migration in SUM149 cells. | PMC11276844 |
In Vivo:
Administration | Dosage | Frequency | Description | Reference |
SCID mice | CWR22Rv1 xenograft model | Oral (p.o) | 1.5 mg/kg | Single injection, observed for 6 days | Niclosamide and bicalutamide combination treatment significantly suppressed the growth of CWR22Rv1 xenografts, indicating that the combination therapy can overcome enzalutamide resistance. | PMC5544572 |
Mice | KI AR113Q mouse model | Subcutaneous injection | 20 mg/kg | Single dose 2 hours before, lasting for 14 days | Bicalutamide and trehalose ameliorated SBMA pathology, extended the survival of mice, improved motor behavior, and partially recovered muscle morphology. Bicalutamide also prevented the formation of AR insoluble forms and possibly restored the autophagic flux. | PMC10121997 |
Balb/SCID mice | IPC-366 and SUM149 cell xenograft model | Bicalutamide: drinking water; Docetaxel and Doxorubicin: intraperitoneal injection | 25 mg/kg | 3 weeks | To evaluate the effect of bicalutamide combined with docetaxel and doxorubicin on tumor growth. Results showed that the triple combination significantly reduced tumor volume in IPC-366 and SUM149 mice. | PMC11276844 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00298155 | Cancer Prosta... More >>te Neoplasms Less << | Phase 2 | Completed | - | United States, Washington ... More >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 Less << |
NCT00298155 | - | Completed | - | - | |
NCT02064036 | Adenocarcinoma of the Prostate | Not Applicable | Recruiting | October 2018 | United States, California ... More >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD 916-724-8295 rkvalicenti@ucdavis.edu Principal Investigator: Richard Valicenti, MD Less << |
NCT00567580 | Prostate Cancer | Phase 3 | Active, not recruiting | December 2025 | - |
NCT00769795 | Prostate Cancer | Phase 2 | Completed | - | United States, Washington ... More >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 University of Washington Medical Center Seattle, Washington, United States, 98195 Less << |
NCT02346578 | Castration-resistant Prostate ... More >>Cancer Less << | Phase 2 | Active, not recruiting | March 2020 | Japan ... More >> Osaka City University Graduate School of Medicine Osaka, Japan Less << |
NCT01120262 | - | Completed | - | - | |
NCT02615223 | Stage IV Prostate Cancer | Not Applicable | Unknown | December 2018 | China, Tianjin ... More >> Tianjin Medical University Cancer Institute and Hospital Recruiting Tianjin, Tianjin, China, 300060 Contact: Zhi Guo, PhD 02223340123 ext 1095 cjr.guozhi@vip.163.com Contact: Tongguo Si, PhD 02223340123 ext 1095 sitg77@163.com Less << |
NCT00004124 | - | Active, not recruiting | - | - | |
NCT03119857 | Prostatic Neoplasms | Phase 3 | Active, not recruiting | December 2023 | Denmark ... More >> Copenhagen University hospital, Rigshospitalet Copenhagen, Denmark Finland Kuopio University Hospital Kuopio, Kuopio Kuopio, Finland, 70211 Turku University Hospital Turku, Finland, 20521 Netherlands Erasmus Medical Center Rotterdam Rotterdam, Netherlands, 3015 CE Sweden Sahlgrenska University Hospital Göteborg, Sweden, 41345 Less << |
NCT00536653 | Osteoporosis | Not Applicable | Completed | - | United Kingdom ... More >> Wirral University Hospitals NHS Trust Upton, Wirral, Merseyside, United Kingdom, CH48 5PE Less << |
NCT00514917 | Prostatic Neoplasms | Phase 3 | Terminated(Company decision to... More >> discontinue the study, not due to any safety or efficacy concerns) Less << | - | United States, New Jersey ... More >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Belgium Sanofi-Aventis Administrative Office Diegem, Belgium Canada Sanofi-Aventis Administrative Office Laval, Canada Czech Republic Sanofi-Aventis Administrative Office Praha, Czech Republic Germany Sanofi-Aventis Administrative Office Frankfurt, Germany Lithuania Sanofi-Aventis Administrative Office Vilnius, Lithuania Poland Sanofi-Aventis Administrative Office Warsaw, Poland Slovakia Sanofi-Aventis Administrative Office Bratislava, Slovakia Spain Sanofi-Aventis Administrative Office Barcelona, Spain Less << |
NCT00514917 | - | Terminated(Company decision to... More >> discontinue the study, not due to any safety or efficacy concerns) Less << | - | - | |
NCT01342367 | Prostate Cancer | Not Applicable | Recruiting | April 2019 | United States, Illinois ... More >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Fauzia Arif farif@radonc.uchicago.edu Less << |
NCT02716974 | Prostate Cancer | Phase 2 | Recruiting | March 2021 | United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Channing Paller, MD 202-660-6500 cpaller1@jhmi.edu United States, Maryland Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21205 Johns Hopkins Bayview Medical Center Recruiting Baltimore, Maryland, United States, 21224 Contact: Christian Pavlovich, MD 410-550-3338 cpavlov2@jhmi.edu Less << |
NCT00666666 | Adenocarcinoma of the Prostate... More >> Stage IV Prostate Cancer Less << | Phase 2 | Completed | - | United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less << |
NCT02918968 | Prostate Cancer | Phase 4 | Active, not recruiting | March 2020 | Japan ... More >> Site JP00024 Aichi, Japan Site JP00025 Aichi, Japan Site JP00010 Chiba, Japan Site JP00053 Chiba, Japan Site JP00038 Ehime, Japan Site JP00039 Fukuoka, Japan Site JP00040 Fukuoka, Japan Site JP00050 Fukuoka, Japan Site JP00051 Fukuoka, Japan Site JP00005 Gunma, Japan Site JP00043 Gunma, Japan Site JP00045 Gunma, Japan Site JP00035 Hiroshima, Japan Site JP00001 Hokkaido, Japan Site JP00002 Hokkaido, Japan Site JP00048 Hokkaido, Japan Site JP00054 Hokkaido, Japan Site JP00055 Ibaraki, Japan Site JP00019 Kanagawa, Japan Site JP00020 Kanagawa, Japan Site JP00021 Kanagawa, Japan Site JP00044 Kanagawa, Japan Site JP00026 Kyoto, Japan Site JP00006 Nagano, Japan Site JP00008 Nagano, Japan Site JP00041 Nagasaki, Japan Site JP00046 Nara, Japan Site JP00033 Okayama, Japan Site JP00027 Osaka, Japan Site JP00028 Osaka, Japan Site JP00029 Osaka, Japan Site JP00030 Osaka, Japan Site JP00031 Osaka, Japan Site JP00032 Osaka, Japan Site JP00042 Saga, Japan Site JP00009 Saitama, Japan Site JP00022 Shizuoka, Japan Site JP00049 Tochigi, Japan Site JP00037 Tokushima, Japan Site JP00011 Tokyo, Japan Site JP00013 Tokyo, Japan Site JP00014 Tokyo, Japan Site JP00016 Tokyo, Japan Site JP00017 Tokyo, Japan Site JP00018 Tokyo, Japan Site JP00052 Toyama, Japan Site JP00034 Yamaguchi, Japan Less << |
NCT00666666 | - | Completed | - | - | |
NCT01642732 | Prostate Cancer | Phase 1 | Terminated(Lack of accrual and... More >> funding expires in June, 2014.) Less << | - | United States, District of Col... More >>umbia Georgetown University Washington, D.C., District of Columbia, United States, 20057 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Less << |
NCT01642732 | - | Terminated(Lack of accrual and... More >> funding expires in June, 2014.) Less << | - | - | |
NCT00702923 | Prostate Cancer | Phase 1 | Terminated(Enrollment was halt... More >>ed prematurely due to slow accrual.) Less << | - | United States, Wisconsin ... More >> University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Less << |
NCT00684905 | Prostate Cancer | Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 Less << |
NCT00943956 | Prostate Cancer | Phase 1 | Completed | - | France ... More >> Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier, France, 34298 Less << |
NCT00021450 | Prostate Cancer | Phase 3 | Completed | - | Belgium ... More >> Academisch Ziekenhuis der Vrije Universiteit Brussel Brussels, Belgium, 1090 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Cyprus Bank Of Cyprus Oncology Centre Nicosia, Cyprus, 2006 Strovolos Czech Republic Charles University Hospital Hradec Kralove, Czech Republic, 500 05 France Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz Besancon, France, 25030 Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon, France, 21079 CHU de Grenoble - Hopital de la Tronche Grenoble, France, 38043 Centre Paul Strauss Strasbourg, France, 67085 Centre d'Oncologie Saint-Yves Vannes, France, 56001 Ireland Saint Luke's Hospital Dublin, Ireland, 6 Italy Spedali Civili di Brescia Brescia, Italy, 25124 Istituto Nazionale per la Ricerca sul Cancro Genoa, Italy, 16132 Luxembourg Hopital de la Ville D'Esch-sur-Alzette Esch-sur-Alzette, Luxembourg, L-4240 Netherlands Arnhems Radiotherapeutisch Instituut Arnhem, Netherlands, 6815 AD University Medical Center Groningen Groningen, Netherlands, 9700 RB Dr. Bernard Verbeeten Instituut Tilburg, Netherlands, 5042 SB Poland Medical University of Gdansk Gdansk, Poland, 80-211 Spain Institut Catala d'Oncologia - Hospital Duran i Reynals Barcelona, Spain, 08907 United Kingdom Belfast City Hospital Trust Incorporating Belvoir Park Hospital Belfast, Northern Ireland, United Kingdom, BT8 8JR Less << |
NCT00004124 | Prostate Cancer | Phase 3 | Active, not recruiting | June 1, 2022 | - |
NCT00349557 | Prostate Cancer | Phase 2 | Completed | - | United States, Washington ... More >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 Less << |
NCT00067015 | Prostate Cancer | Phase 3 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less << |
NCT00014586 | Prostate Cancer | Phase 3 | Terminated(low accrual) | - | Germany ... More >> Center of Operative Urology Bremen Bremen, Germany, D-28277 Less << |
NCT00702923 | - | Terminated(Enrollment was halt... More >>ed prematurely due to slow accrual.) Less << | - | - | |
NCT01415778 | Healthy | Phase 1 | Completed | - | - |
NCT02085252 | Prostate Cancer | Phase 3 | Completed | - | France ... More >> Tenon Hospital Paris France Paris, France, 75020 Ouzid, Paris La Défense, Paris, France, 92977 Less << |
NCT00924807 | Prostate Cancer | Phase 1 Phase 2 | Terminated(Sponsor closed the ... More >>trial) Less << | - | United States, New York ... More >> St.Luke's-Roosevelt Hospital Center New York, New York, United States, 10019 Less << |
NCT00319787 | Locally Advanced Prostate Canc... More >>er Less << | Phase 2 | Completed | - | Norway ... More >> Research Site Moelv, Norway Research Site Oslo, Norway Research Site Trondheim, Norway Less << |
NCT00255268 | Metastatic Prostate Cancer | Phase 4 | Withdrawn | - | Mexico ... More >> Research Site Metepec, Mexico Research Site Mexico City, Mexico Less << |
NCT01020305 | Prostate Cancer ... More >> Prostatic Neoplasms Castrate-resistant Prostate Cancer (CRPC) Androgen-insensitive Prostate Cancer Hormone-refractory Prostate Cancer Metastatic Disease Less << | Phase 1 Phase 2 | Terminated(Decision by funding... More >> sponsor due to poor accrual) Less << | - | United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less << |
NCT02582749 | Prostate Cancer ... More >> Bone Metastases Prostate Neoplasms Less << | Phase 2 | Active, not recruiting | January 2020 | United States, Arizona ... More >> University of Arizona Cancer Center at Dignity Health St. Joseph's Phoenix, Arizona, United States, 85004 United States, Illinois Illinois CancerCare, P. C. Peoria, Illinois, United States, 61615 United States, Indiana Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States, 46219 United States, Iowa University of Iowa Hopital and Clinics Iowa City, Iowa, United States, 52242 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Henry Ford Hospital Detroit, Michigan, United States, 48202 Metro Health Cancer Center Wyoming, Michigan, United States, 49519 United States, Nebraska GU Research Network, LLC Omaha, Nebraska, United States, 68130 United States, New York Integrated Medical Professionals, PLLC Lake Success, New York, United States, 11042 United States, Texas University of Texas Medical Branch at Galveston Galveston, Texas, United States, 77555 United States, Wisconsin Clement J. Zablocki VA Medical Center Milwaukee, Wisconsin, United States, 53295 Less << |
NCT01020305 | - | Terminated(Decision by funding... More >> sponsor due to poor accrual) Less << | - | - | |
NCT00470834 | Neoplasms, Prostate | Phase 4 | Completed | - | - |
NCT00470834 | - | Completed | - | - | |
NCT00919477 | - | Completed | - | - | |
NCT01120236 | Prostate Adenocarcinoma ... More >> Recurrent Prostate Carcinoma Stage IV Prostate Cancer Less << | Phase 2 | Completed | - | - |
NCT01120236 | - | Completed | - | - | |
NCT00188708 | Prostatic Neoplasms | Phase 2 | Active, not recruiting | April 2019 | Canada, Ontario ... More >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00924807 | - | Terminated(Sponsor closed the ... More >>trial) Less << | - | - | |
NCT00688532 | - | Completed | - | - | |
NCT00421694 | Prostate Cancer | PHASE2|PHASE3 | COMPLETED | - | University of L'Aquila, L'Aqui... More >>la, Abruzzo, 67100, Italy Less << |
NCT00418080 | Prostate Cancer | Phase 2 | Completed | - | Italy ... More >> University of L'Aquila L'Aquila, Abruzzo, Italy, 67100 Less << |
NCT00293696 | Prostate Cancer | Phase 4 | Completed | - | Finland ... More >> TUCH Tampere, Finland, 33521 Less << |
NCT02382094 | Prostate Cancer | PHASE3 | COMPLETED | 2025-07-12 | - |
NCT00233610 | Prostate Cancer | Phase 3 | Completed | - | Italy ... More >> Research Site Bari, BA, Italy Research Site Bologna, BO, Italy Research Site Catania, CT, Italy Research Site Bagno a Ripoli, FI, Italy Research Site Firenze, FI, Italy Research Site Genova, GE, Italy Research Site Pisa, PI, Italy Research Site Parma, PR, Italy Research Site Udine, UD, Italy Research Site Como, Italy Research Site Roma, Italy Less << |
NCT00637871 | Gynaecomastia ... More >> Prostate Cancer Less << | Phase 2 | Completed | - | - |
NCT03358563 | Prostate Cancer | Early Phase 1 | Recruiting | January 2020 | United States, Wisconsin ... More >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 800-622-8922 cancerconnect@uwcarbone.wisc.edu Principal Investigator: Christos Kyriakopoulos, MD Less << |
NCT00672282 | Non-Metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT00430235 | Adenocarcinoma of the Prostate | Phase 2 | Completed | - | Canada, British Columbia ... More >> BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Less << |
NCT00833248 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00086736 | Prostate Cancer | Phase 2 | Completed | - | United States, Alabama ... More >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3300 Less << |
NCT00659438 | Prostate Cancer | Phase 2 | Completed | - | France ... More >> Research Site Bordeaux Cedex, France Research Site Creteil, France Research Site Paris, France Research Site Reims Cedex, France Research Site Villejuif, France Less << |
NCT00659438 | - | Completed | - | - | |
NCT00884273 | - | Completed | - | - | |
NCT00012090 | Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less << | Phase 2 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less << |
NCT00831233 | Prostate Cancer | Phase 3 | Terminated(Poor recruitment du... More >>e to rare targeted population) Less << | - | Germany ... More >> Facharztpraxis für Urologie Bamberg, Germany, 96047 Gemeinschaftspraxis Borken, Germany, 46325 Universitätsklinikum Dresden Dresden, Germany, 01307 Euromed Clinic Fürth, Germany, 90763 Urologische Gemeinschaftspraxis Hamburg, Germany, 22399 Gemeinschaftspraxis Köln, Germany, 50667 VITURO Gesellschaft für Klinische Studien Leipzig, Germany, 04109 Klinikum Offenbach GmbH Offenbach, Germany, 63069 Urologische Klinik Planegg Planegg, Germany, 82152 Wuppertaler Gemeinschaftspraxis Wuppertal, Germany, 42103 Spain Hospital Universitario Principe de Asturias Alcalá de Henares-Madrid, Spain, 28805 Fundacion Hospital Alcorcón Alcorcon, Spain, 28922 Fundación Puigvert Barcelona, Spain, 08025 Hospital de Basurto Bilbao (Bizkaia), Spain, 48013 Complejo Hospitalario Universitario A Coruña Coruña, Spain Hospital universitario Ramón y Cajal Madrid, Spain, 28034 Hospital Clinico Universitario S. Carlos Madrid, Spain, 28040 Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 28222 Hospital Manacor Manacor, Spain, 07500 Hospital Universitario Central de Asturias Oviedo, Spain, 33006 Hospital Santiago de Compostela Santiago de Compostela, Spain, 15706 Hospital Virgen Macarena Sevilla, Spain, 41014 Hospital Xeral de Vigo Vigo, Spain, 36204 United Kingdom United Bristol Healthcare NHSTrust Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Falkirk and District Royal Infirmary Falkirk, United Kingdom, FK1 5QE Southern General Hospital Glasgow, United Kingdom, G51 4TF Castle Hill Hospital Hull, United Kingdom, HU16 5JQ Whipps Cross University Hospital London, United Kingdom, E11 1NR The Royal Free Hospital London, United Kingdom, NW3 2QG King's College Hospital London, United Kingdom, SE5 9RS Derriford Hospital Plymouth, United Kingdom, PL6 8DH Royal Hallamshire Hospital, Sheffield South Sheffield, United Kingdom, S10 2JF Sunderland Royal Hospital Sunderland, United Kingdom, SR4 7TP Less << |
NCT00777959 | Prostate Cancer | Phase 2 | Completed | - | - |
NCT01658527 | Prostate Cancer | Phase 2 | Withdrawn(Pharmaceutical compa... More >>ny has terminated orteronel (TAK-700) development for Prostate Cancer) Less << | January 2017 | Belgium ... More >> Onze Lieve Vrouw Ziekenhuis Aals, Belgium Cliniques Universitaires Saint-Luc Brussels, Belgium AZ Groeninge Kortrijk - Campus Vercruysselaan Kortrijck, Belgium CHU Dinant Godinne - UCL Namur Yvoir, Belgium Less << |
NCT00554086 | Prostate Cancer | Phase 2 | Completed | - | Canada, Ontario ... More >> Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Less << |
NCT00590213 | Prostate Cancer | Phase 4 | Completed | - | Turkey ... More >> Research Site Adana, Turkey Research Site Ankara, Turkey Research Site Diyarbak?r, Turkey Research Site Edirne, Turkey Research Site Eskisehir, Turkey Research Site Istanbul, Turkey Research Site Izmir, Turkey Research Site Manisa, Turkey Research Site Samsun, Turkey Less << |
NCT00831233 | - | Terminated(Poor recruitment du... More >>e to rare targeted population) Less << | - | - | |
NCT03520478 | Prostate Cancer ... More >> Hormone-Dependent Prostate Cancer Less << | Phase 3 | Recruiting | April 30, 2025 | China ... More >> Ye Dingwei Recruiting Shanghai, China Contact: Dingwei Ye, Doctor Less << |
NCT00878436 | Prostate Cancer ... More >> Prostatic Neoplasms Less << | Phase 1 Phase 2 | Completed | - | United States, New Jersey ... More >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Less << |
NCT00833248 | - | Completed | - | - | |
NCT01416883 | Healthy | Phase 1 | Terminated | - | - |
NCT00841113 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00673205 | Non-Metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT02058706 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Stage IV Prostate Cancer Less << | Phase 2 | Active, not recruiting | December 31, 2018 | United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less << |
NCT00636259 | - | - | - | - | |
NCT00878436 | - | Completed | - | - | |
NCT00486642 | Hormone-Resistant Prostate Can... More >>cer Recurrent Prostate Carcinoma Less << | Phase 2 | Completed | - | Canada, British Columbia ... More >> BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00685633 | Prostate Cancer | Phase 2 | Withdrawn | - | - |
NCT00486642 | - | Completed | - | - | |
NCT00959335 | Prostate Cancer ... More >> Hirsutism Less << | Phase 1 | Completed | - | - |
NCT01050842 | Prostate Cancer ... More >> Adenocarcinoma of the Prostate Hormone-resistant Prostate Cancer Stage IV Prostate Cancer Less << | Early Phase 1 | Completed | - | United States, Arizona ... More >> Mayo Clinic In Arizona Scottsdale, Arizona, United States, 85259 Less << |
NCT00031889 | Prostate Cancer | Phase 2 | Completed | - | Switzerland ... More >> Kantonspital Aarau Aarau, Switzerland, 5001 University Hospital Basel, Switzerland, CH-4031 Inselspital, Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2500 Kantonsspital Bruderholz Bruderholz, Switzerland, CH-4101 Ratisches Kantons und Regionalspital Chur, Switzerland, CH-7000 Clinique De Genolier Genolier, Switzerland, Ch-1272 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Istituto Oncologico della Svizzera Italiana Lugano, Switzerland, CH-6900 Ospedale Beata Vergine Mendrisio, Switzerland, CH-6850 Institut Central des Hopitaux Valaisans Sion, Switzerland, CH1951 Universitaetsspital Zurich, Switzerland, CH-8091 Less << |
NCT01200810 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Stage IV Prostate Cancer Less << | Phase 2 | Terminated(Drug was no longer ... More >>available) Less << | - | United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less << |
NCT00884273 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00002874 | Prostate Cancer | Phase 3 | Active, not recruiting | - | - |
NCT01200810 | - | Terminated(Drug was no longer ... More >>available) Less << | - | - | |
NCT00002874 | - | Active, not recruiting | - | - | |
NCT00657904 | Non-metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT01039233 | Bioequivalency | Phase 1 | Completed | - | Canada, Quebec ... More >> SFBC Anapharm Montreal, Quebec, Canada, H3X 2H9 Less << |
NCT00871585 | - | Completed | - | Croatia ... More >> Research Site Cakovec, Croatia Research Site Dubrovnik, Croatia Research Site Karlovac, Croatia Research Site Pula, Croatia Research Site Rijeka, Croatia Research Site Sibenik, Croatia Research Site Sisak, Croatia Research Site Slavonski brod, Croatia Research Site Split, Croatia Research Site Vinkovci, Croatia Research Site Virovitica, Croatia Research Site Vukovar, Croatia Research Site Zabok, Croatia Research Site Zadar, Croatia Research Site Zagreb, Croatia Less << | |
NCT00468715 | Breast Cancer | Phase 2 | Active, not recruiting | March 2019 | United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, District of Columbia Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Massachusetts Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, New York Ralph Lauren Center for Cancer Care and Prevention New York, New York, United States, 10035 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Duke Cancer Institute Durham, North Carolina, United States, 27710 Less << |
NCT00094328 | Puberty, Precocious | Phase 2 | Completed | - | United States, Alabama ... More >> Research Site Birmingham, Alabama, United States, 35233 United States, Florida Research Site Jacksonville, Florida, United States, 32207 United States, Indiana Research Site Indianapolis, Indiana, United States, 46202 United States, Minnesota Research Site Minneapolis, Minnesota, United States, 55416 United States, Oklahoma Research Site Tulsa, Oklahoma, United States, 74136 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19134 United States, South Carolina Research Site Greenville, South Carolina, United States, 29615 United States, Texas Research Site Temple, Texas, United States, 76508 United States, Washington Research Site Spokane, Washington, United States, 99204 Canada, Ontario Research Site London, Ontario, Canada, N6A 4G5 France Research Site Montpellier Cedex, France, 34295 India Research Site Chennai, India, 600020 Research Site New Dehli, India, 110029 Russian Federation Research Site Moscow, Russian Federation, 117036 United Kingdom Research Site London, United Kingdom, WC1N 3JH Less << |
NCT00757692 | Prostate Cancer | Phase 2 | Completed | - | Canada, British Columbia ... More >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Less << |
NCT00960310 | Prostate Cancer ... More >> Hirsutism Less << | Phase 1 | Completed | - | - |
NCT03147196 | Stage I Prostate Adenocarcinom... More >>a Stage II Prostate Adenocarcinoma Less << | Phase 2 | Recruiting | June 2022 | United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office 855-776-0015 Mangskau.Toni@mayo.edu Principal Investigator: Erik P. Castle Less << |
NCT01251861 | Recurrent Prostate Carcinoma ... More >> Stage I Prostate Cancer AJCC v7 Stage IIA Prostate Cancer AJCC v7 Stage IIB Prostate Cancer AJCC v7 Stage III Prostate Cancer AJCC v7 Less << | Phase 2 | Active, not recruiting | - | - |
NCT01416870 | Healthy | Phase 1 | Terminated | - | - |
NCT00094328 | - | Completed | - | - | |
NCT00973050 | Healthy | Phase 1 | Completed | - | Canada, Quebec ... More >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 Less << |
NCT01664923 | Prostate Cancer | Phase 2 | Completed | - | - |
NCT01664923 | - | Completed | - | - | |
NCT02614859 | Cancer of Prostate | Phase 2 | Recruiting | April 2022 | United States, Maryland ... More >> National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892-9760 Contact: Marijo Bilusic, MD marijo.bilusic@nih.gov United States, Pennsylvania Fox Chase Cancer Center - Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19111-2497 Less << |
NCT00972855 | Healthy | Phase 1 | Completed | - | Canada, Quebec ... More >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 Less << |
NCT00814788 | - | Completed | - | - | |
NCT00551044 | Prostatic Neoplasms | COMPLETED | 2025-08-05 | Wirral University Teaching Hos... More >>pitals NHS Trust, Upton, Wirral, Merseyside, CH48 5PE, United Kingdom Less << | |
NCT03650894 | Breast Neoplasm Female ... More >> Breast Cancer Breast Carcinoma Breast Tumor Less << | Phase 2 | Not yet recruiting | October 2023 | United States, Oregon ... More >> Providence Oncology & Hematology Care Clinic - Eastside Not yet recruiting Portland, Oregon, United States, 97213 Sub-Investigator: Rachel Sanborn, MD Sub-Investigator: Alison Conlin, MD Sub-Investigator: Todd Crocenzi, MD Sub-Investigator: Brendan Curti, MD Sub-Investigator: John Godwin, MD Sub-Investigator: Rom Leidner, MD Sub-Investigator: Rui Li, MD, PhD Sub-Investigator: Walter Urba, MD, PhD Principal Investigator: David Page, MD Sub-Investigator: Herschel Wallen, MD Sub-Investigator: Moran Amy, PhD Less << |
NCT03090165 | Triple Negative Breast Cancer | Phase 1 Phase 2 | Recruiting | September 2019 | United States, Illinois ... More >> University of Illinois Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Ayesha Zaidi 312-413-1902 azaidi22@uic.edu Principal Investigator: Kent Hoskins, MD United States, Michigan Michigan State University Recruiting Lansing, Michigan, United States, 48910 Contact: Karen Luellen 517-975-9534 karen.luellen@hc.msu.edu Principal Investigator: Deimante Tamkus, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Alison Haegler 732-235-8060 agh46@cinj.rutgers.edu Principal Investigator: Nancy Chan, MD United States, Pennsylvania Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Sean Flemings 717-531-5364 sfleming1@pennstatehealth.psu.edu Principal Investigator: Cristina Truica, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 608-262-5223 cancerconnect@uwcarbone.wisc.edu Less << |
NCT01288911 | Prostatic Neoplasms | Phase 2 | Completed | - | - |
NCT00630344 | Prostate Cancer | Phase 2 | Completed | - | United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less << |
NCT00846976 | Prostate Cancer | PHASE3 | COMPLETED | 2025-06-13 | Research Site, New York, New Y... More >>ork, United States Less << |
NCT01288911 | - | Completed | - | - | |
NCT02605486 | Metastatic Breast Cancer (MBC) | Phase 1 Phase 2 | Recruiting | November 2020 | United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Ayca Gucalp, MD 646-888-4536 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Ayca Gucalp, MD 646-888-4536 Less << |
NCT01809691 | Prostate Cancer | Phase 3 | Active, not recruiting | October 2027 | - |
NCT00866554 | Prostate Cancer ... More >> Erectile Dysfunction Lower Urinary Tract Symptoms Less << | Phase 2 | Unknown | December 2015 | Canada ... More >> CHUQ- Hotel-Dieu de Quebec Quebec, Canada, G1R 2J6 Less << |
NCT01044706 | Healthy | PHASE1 | COMPLETED | 2025-07-05 | SFBC Anapharm, sainte-Foy, Que... More >>bec, G1V 2K8, Canada Less << |
NCT00814788 | Prostate Cancer | Phase 2 | Completed | - | United States, California ... More >> University of California Davis Cancer Center Sacramento, California, United States, 95817 Less << |
NCT02910050 | Breast Cancer | Phase 2 | Recruiting | December 2018 | China, Guangdong ... More >> State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Fei Xu, MD +86-13711277870 xufei@sysucc.org.cn Less << |
NCT01044706 | Healthy | PHASE1 | COMPLETED | 2025-07-05 | SFBC Anapharm, sainte-Foy, Que... More >>bec, G1V 2K8, Canada Less << |
NCT02348281 | Breast Cancer | PHASE2 | TERMINATED | 2025-12-15 | Fudan University Shanghai Canc... More >>er Center, Shanghai, 200032, China Less << |
NCT02353988 | Breast Neoplasms | Phase 2 | Unknown | May 2017 | - |
NCT02146937 | Detectable Prostate Nodules | Phase 2 | Withdrawn(Due to lack of accru... More >>al for this study. PI decided to close the study.) Less << | - | United States, Maryland ... More >> Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 Less << |
NCT02697032 | Breast Cancer | Phase 2 | Recruiting | April 2019 | Netherlands ... More >> University Medical Center Groningen Recruiting Groningen, Netherlands, 9713 GZ Contact: C. P. Schröder, MD, PhD +3150 3612821 c.p.schroder@umcg.nl Contact: G. A.P. Hospers, MD, PhD +31 50 3612821 g.a.p.hospers@umcg.nl Principal Investigator: C. P. Schröder, MD, PhD Less << |
NCT03055312 | Metastatic Triple Negative Bre... More >>ast Cancer Less << | Phase 3 | Recruiting | December 2020 | China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhong-yu Yuan, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Yong-yi Zhong, BD 86-20-87342635 zhongyy@sysucc.org.cn Sun Yat-sen University, Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Yuan Zhong-yu, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Huang Jia-Jia, MD 86-20-87343794 huangjiaj@sysucc.org.cn Principal Investigator: Yuan Zhong-yu, MD Sub-Investigator: Huang Jia-Jia, MD Less << |
NCT00630344 | - | Completed | - | - | |
NCT02487823 | Non Castrate Metastatic Prosta... More >>te Cancer Less << | Phase 1 | Terminated(Defect of recruitme... More >>nt) Less << | - | France ... More >> Institut Paoli Calmettes Marseille, France, 13009 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 2.32mL 0.46mL 0.23mL | 11.62mL 2.32mL 1.16mL | 23.24mL 4.65mL 2.32mL | |
Dissolving Methods | in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|